Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2021-12-09 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司第四届监事会第十一次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolutions passed at the 11th meeting of the 4th Supervisory Board of Changchun Baike Biotechnology Co., Ltd. It includes details about the meeting attendance, voting results on various proposals such as the 2022 related party transaction limits, appointment of the 2021 financial audit and internal control audit institutions, and nomination of candidates for the 5th Supervisory Board. The document references other announcements published on the Shanghai Stock Exchange website for more detailed information. The document is short (1504 characters) and primarily serves as a formal announcement of meeting resolutions rather than a full report or detailed financial data. It does not contain financial statements or detailed audit reports itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-09 Chinese
长春百克生物科技股份公司关于2022年度日常关联交易额度预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected amount of daily related party transactions for the year 2022 by Changchun Baike Biotechnology Co., Ltd. It includes details about the nature of the transactions, the related parties involved, the approval process by the board and independent directors, and the opinion of the sponsor institution. The document does not contain financial statements or comprehensive financial data but rather focuses on disclosure of related party transaction estimates and compliance with regulatory requirements. It is a regulatory announcement about related party transactions rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS). The document length is 4149 characters, which is relatively short and consistent with an announcement rather than a full report.
2021-12-09 Chinese
长春百克生物科技股份公司第四届董事会独立董事关于第四届董事会第二十次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is titled as an independent opinion from the independent directors of the company regarding matters discussed at the 20th meeting of the 4th Board of Directors. It includes opinions on related party transactions, appointment of the 2021 financial audit firm, and nominations for the 5th Board of Directors. The content focuses on board and director matters, including nominations and qualifications of directors, and audit firm appointment, but does not contain financial statements or detailed financial results. It is not an annual report, audit report, or earnings release. The document is clearly related to board and management information, specifically about board nominations and audit firm appointment, which fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication but an independent opinion document. Therefore, the classification is MANG with high confidence.
2021-12-09 Chinese
中信证券股份有限公司关于长春百克生物科技股份公司2021年持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "现场检查报告" (on-site inspection report) related to the continuous supervision work by the sponsor (中信证券股份有限公司) for the listed company 长春百克生物科技股份公司 for the year 2021. It details the sponsor's review of governance, internal controls, information disclosure, independence, use of raised funds, related party transactions, and operational status. The document is a detailed report of the sponsor's supervisory activities and findings rather than a general annual report or financial statement. It is not an announcement or a brief summary but a substantive report on regulatory compliance and supervision. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of regulatory or internal checks, excluding full annual reports. The document length is under 5,000 characters but contains detailed substantive content, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2021
2021-12-03 Chinese
长春百克生物科技股份公司关于前董事长亲属短线交易及致歉的公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding the short-swing trading activities of a former chairman's relative and the company's response and remedial measures. It details specific share transactions, legal references to securities law, and the resignation of the former chairman. There are no financial statements, earnings data, or report attachments. The content focuses on insider trading disclosures and compliance measures, which aligns with a Director's Dealing report rather than a full financial report or other categories. The document length is short and it is a standalone announcement about insider transactions.
2021-11-04 Chinese
长春百克生物科技股份公司2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 年第三季度报告' which translates to '2021 Third Quarter Report'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes for the third quarter of 2021. The document includes unaudited financial statements and management assurances about the accuracy and completeness of the quarterly report. The presence of comprehensive financial data for a period shorter than a full fiscal year (quarterly data) and the detailed financial tables confirm this is a quarterly financial report. There is no indication that this is an announcement of a report or a certification letter, but the full report itself. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2021
2021-10-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.